 BOSTON, MA ACCESSWIRE August 24, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor CTGF inhibitor the Company is developing for the treatment of idiopathic pulmonary fibrosis IPF via oral inhaled administration, at the European Respiratory Society ERS International Congress 2021. The poster is now available for viewing by registered participants, and a copy of the poster is available here. 